PCRX Pacira BioSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCRX

Price (delayed)

$25.39

Market cap

$999.04M

P/E Ratio

211.58

Dividend/share

N/A

EPS

$0.12

Enterprise value

$1.27B

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 48
Relative Valuation: Rel. Valuation: 55
Relative Profitability: Rel. Profitability: 62

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...

Highlights
The company's quick ratio has surged by 58% YoY
Pacira BioSciences's debt has decreased by 35% YoY
Pacira BioSciences's EPS has surged by 105% YoY but it has decreased by 25% QoQ
The company's net income has surged by 105% YoY but it fell by 27% QoQ
The equity has declined by 18% year-on-year and by 6% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.pacira.com
Peers: HRTX CPIX TVRD OMER

Key stats

What are the main financial stats of PCRX

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
1.44%
1 week
4.19%
1 month
14.11%
1 year
9.39%
YTD
-1.89%
QTD
0.08%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$734.86M
Gross profit
$583.01M
Operating income
$24.1M
Net income
$5.14M
Gross margin
79.3%
Net margin
0.7%
The company's operating income has surged by 128% YoY and by 26% QoQ
PCRX's operating margin has soared by 128% YoY and by 27% QoQ
Pacira BioSciences's net margin has soared by 105% YoY but it has decreased by 30% from the previous quarter
The company's net income has surged by 105% YoY but it fell by 27% QoQ

Price vs fundamentals

How does PCRX's price correlate with its fundamentals

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
PCRX P/E details
P/E
211.58
P/B
1.67
P/S
1.4
EV/EBIT
42.58
EV/EBITDA
10.47
EV/Sales
1.72
Pacira BioSciences's EPS has surged by 105% YoY but it has decreased by 25% QoQ
PCRX's P/B is 24% below its 5-year quarterly average of 2.2 but 11% above its last 4 quarters average of 1.5
The equity has declined by 18% year-on-year and by 6% since the previous quarter
The price to sales (P/S) is 46% lower than the 5-year quarterly average of 2.6 and 7% lower than the last 4 quarters average of 1.5
The revenue has grown by 4.6% YoY

Efficiency

How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROIC has soared by 168% YoY but it has decreased by 10% from the previous quarter
Pacira BioSciences's return on sales has surged by 156% YoY but it has decreased by 15% QoQ
Pacira BioSciences's ROA has soared by 106% YoY but it has decreased by 20% from the previous quarter
PCRX's ROE has soared by 105% year-on-year but it is down by 22% since the previous quarter

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 118% greater than the total liabilities
The current ratio has soared by 96% YoY and by 4.2% from the previous quarter
The company's quick ratio has surged by 58% YoY
Pacira BioSciences's debt is 37% less than its equity
Pacira BioSciences's debt has decreased by 35% YoY
Pacira BioSciences's debt to equity has decreased by 21% YoY but it has increased by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.